ACQUISITIONS - Acquisition of Beacon Bio (Details) - USD ($) $ in Millions |
1 Months Ended | |
---|---|---|
Jun. 10, 2021 |
Jul. 31, 2020 |
|
Business Acquisition [Line Items] | ||
Vesting period | 4 years | |
Beacon Bio | ||
Business Acquisition [Line Items] | ||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 6.1 | |
Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares | 334,370 | |
Asset Acquisition, Payment made at Closing | $ 0.2 | |
Additional payment | $ 1.0 | |
Vesting period | 3 years | |
Common Stock | Beacon Bio | ||
Business Acquisition [Line Items] | ||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 4.3 |
X | ||||||||||
- Definition The amount of additional amount payable in next twelve months. No definition available.
|
X | ||||||||||
- Definition Number of shares issued on asset acquisition. No definition available.
|
X | ||||||||||
- Definition The amount of cash outflow from asset acquisition at closing. No definition available.
|
X | ||||||||||
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|